New Delhi: Under Aatmanirbhar Bharat 3.0 Mission, COVID Suraksha was announced by the Government of India, to accelerate the development and production of indigenous COVID Vaccines. This is being implemented by Department of Biotechnology, Govt. of India at Biotechnology Industry Research Assistance Council (BIRAC), New Delhi. To augment the capacity of indigenous production of Covaxin…
New Delhi: The Drugs Controller General of India (DCGI), the national regulator, after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trial of Covaxin (COVID vaccine) in the age group of 2 to 18 years, to its manufacturer Bharat Biotech Ltd. The Hyderabad-…
Bengaluru: Union Minister for Chemicals and Fertilizers D.V. Sadananda Gowda (DVS) on Thursday said that a proposal to suspend protection under the Patents Act for Covaxin, the home-made COVID-19 vaccine by Bharat Biotech, is under ‘serious consideration.’ Speaking to newsmen here, he said a Committee had been set up to look at the patent waiver…
Doctors find novel way to convey vaccine availability and eligibility Srirangapatna: Taluk Health Officer Dr. N.K. Venkatesh is wearing a small placard stating “Covaxin is unavailable. Covishield is available for 18-44 and also for 45 years and above, only second dose.” There has been a mad rush of people at the Hospital to take the…
Covishield, Covaxin approved The vaccines are 110 percent safe: Drug Controller General of India Both vaccines to be administered in two doses Can be stored in normal refrigerator New Delhi: It is indeed a red-letter day for India today as two vaccines for COVID-19 produced by Pune-based Serum Institute’s Covishield and Bharat Biotech’s Covaxin, received…
Hyderabad: Covaxin, a vaccine candidate being developed by Bharat Biotech for COVID-19, can offer protection against mutations of Coronavirus, said Krishna Ella, Chairman and Managing Director of the city-based vaccine maker, on Tuesday. He also said the company had approached regulatory authorities seeking approval for an emergency license to use the vaccine, developed in collaboration…
Bharat Biotech Joint Managing Director says it may cost around Rs.300 per dose; Committed to distribute vaccine to ‘Bharat’ first Mysore/Mysuru: All know that Hyderabad-based Bharat Biotech is involved in developing Covaxin, a possible vaccine for the dreaded COVID-19 pandemic. But hardly a few know that two persons behind this company had stayed in ‘Namma…
Bengaluru: Stating that Covaxin trials will be successful in the State, Health and Medical Education Minister Dr. K. Sudhakar said Karnataka is fully prepared for the distribution of COVID-19 vaccine. He was speaking here after the launch of the 3rd phase clinical trials of Bharat Biotech’s Covaxin at Vydehi Institute of Medical Science and Research…
New Delhi: While Phase-1 human trials of Bharat Biotech’s Covaxin, India’s first indigenous COVID-19 vaccine candidate, are on at most of the 12 sites selected by Indian Council of Medical Research (ICMR) across the country, the Post-Graduate Institute of Medical Sciences (PGIMS), Rohtak, has claimed “encouraging” results from first part of tests. Earlier this week,…
Children make merryNovember 14, 2024
Survey numbers missing in MUDA-approved layou...November 14, 2024
‘Priority for girl children’s education’November 14, 2024
Maharani’s students urge CM for Indira Cantee...November 14, 2024
Recent Comments